Clinical Trials · NCT01121939
Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- SCRI Development Innovations, LLC
- Enrollment
- 43
- Start date
- May 2010
- Locations
- 9 sites, United States
- Primary endpoint
- Objective Response Rate (ORR)